R-(−)-Deprenyl hydrochloride
SIGMA/M003 - powder, ≥98% (HPLC)
Synonym: (R)-(−)-N,α-Dimethyl-N-(2-propynyl)phenethylamine hydrochloride; R(−)-N-α-Dimethyl-N-2-propynyl-benzeneethanamine hydrochloride; Selegiline hydrochloride
CAS Number: 14611-52-0
Empirical Formula (Hill Notation): C13H17N · HCl
Molecular Weight: 223.74
MDL Number: MFCD00069299
Linear Formula: C13H17N · HCl
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white |
| form | powder |
| InChI | 1S/C13H17N.ClH/c1-4-10-14 |
| InChI key | IYETZZCWLLUHIJ-UTONKHPSSA |
| mp | 141-142 °C |
| optical activity | [α]25/D −10.8°, c = 6.48 in H2O(lit.) |
| originator | Sanofi Aventis |
| Quality Level | 100 ![]() |
| SMILES string | Cl[H].C[C@H](Cc1ccccc1)N( |
| solubility | H2O: >10 mg/mL |
| Biochem/physiol Actions: | Selective MAO-B inhibitor; anti-Parkinsonian agent. |
| Features and Benefits: | This compound is featured on the Dopamine and Norepinephrine Metabolism and Histamine Synthesis and Metabolism pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here . |
| Features and Benefits: | This compound was developed by Sanofi Aventis . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 1 g in poly bottle |
| Packaging: | 250 mg in poly bottle |
| Symbol | GHS07 |
| Signal word | Warning |
| Hazard statements | H302 - H336 |
| Precautionary statements | P301 + P312 + P330 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 1 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| mp | 141-142 °C |
| UNSPSC | 12352200 |


